Incyte | INCY - Operating Expenses


Incyte reported $5.64B in Operating Expenses for its fiscal quarter ending in September of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 270.57M 450K Sep/2026
Agenus USD -199.08M 22.15M Jun/2026
Agios Pharmaceuticals USD 155.3M 24.53M Jun/2026
Alnylam Pharmaceuticals USD 1.11B 52.78M Sep/2026
Amgen USD 5.69B 6B Sep/2026
BioCryst Pharmaceuticals USD -397.38M 517.17M Sep/2026
Biogen USD 2.32B 663.6M Sep/2026
BioMarin Pharmaceutical USD 819.04M 5.5B Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Eli Lilly USD 10.52B 496M Jun/2026
Exelixis USD 390.27M 10M Sep/2026
Gilead Sciences USD 13.04B 9.09B Sep/2026
Incyte USD 5.64B 4.67B Sep/2026
Ionis Pharmaceuticals USD 373M 2.76M Sep/2026
MacroGenics USD 42.87M 21.68M Jun/2026
Merck USD 10.75B 5.02B Sep/2026
Moderna USD 1.18B 223M Sep/2026
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Neurocrine Biosciences USD 779.7M 40.6M Sep/2026
Novartis USD 9.88B 325M Sep/2026
Novartis USD 13.19B 3.9B Sep/2026
Pfizer USD 89B 3.81B Sep/2026
PTC Therapeutics USD 211.54M 15.12M Jun/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 33.5B 1.79B Sep/2026
Sarepta Therapeutics USD 390.39M 2.43M Sep/2026
Ultragenyx Pharmaceutical USD 283M 6M Sep/2026
Vertex Pharmaceuticals USD 2.18B 118.2M Sep/2026